SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is experiencing heightened volatility, with community discussions focused on the potential impact of recent market liquidations and macroeconomic factors like tariff concerns.  Traders are debating potential support levels and whether this pullback presents a buying opportunity or signals a deeper correction.  Meme coins like $1DOG and $CHINAU are gaining traction, while some traders are wary of shitcoins in general.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight activity around meme tokens like $1DOG, $CHINAU, and $UPDOG, particularly within the Phantom Wallet ecosystem. There's also increasing discussion around Solana's potential for tokenized stock trading and anticipation for a possible SOL ETF approval. Despite recent market volatility, some community members express long-term bullish sentiment and advocate for staking.

1 dog can change your life

The 1DOG crypto is trending as community members highlight its meme energy and potential, particularly within the Phantom Wallet ecosystem. The community emphasizes its strong growth and "loyal vibes," while drawing comparisons to other meme coins. Some users are also pointing to increased volume and potential liquidations.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending amid discussions about a recent market dip and potential buying opportunities, with some community members speculating about orchestrated market manipulation.  Conversations revolve around identifying key resistance levels and predictions for future price movements, while others are discussing the potential impact of upcoming news and long-term prospects for the crypto. There is also discussion about meme coins and specific partnerships within the HBAR ecosystem.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer's cryptocurrency, ICP, is experiencing a surge in community interest, with many users expressing excitement about its current price and potential for long-term gains, while some suggest there is coordinated effort to suppress the coin. The community is actively discussing entry points, staking rewards, and the potential impact of upcoming developments like Caffeine AI, alongside comparing ICP to other altcoins and expressing bullish sentiment despite past performance. Concerns persist around the project's leadership, market manipulation, and broader adoption, with some community members actively expressing frustration around the project's performance.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

PTGX is trending due to positive Phase 2b trial results for their drug Icotrokinra in treating ulcerative colitis, leading to significant price movement and analyst upgrades. Community members are actively discussing the potential for further clinical development and speculating about acquisition possibilities, particularly by Johnson & Johnson, while also watching for upcoming earnings and potential stock offerings. Bullish sentiment is fueled by the drug's potential and high institutional ownership.

Global X Funds - Global X Copper Miners ETF

COPX is trending as the price of copper rises, fueled by optimism about global economic growth and increased demand for the metal in green energy technologies. Community members are discussing the potential for further price increases and the impact on copper mining companies. Some analysts are noting the potential for supply deficits and the benefits for copper producers.

Hydrex is the MetaDEX & Liquidity Infrastructure purpose-built for Base. By combining automated strategies, liquid-backed tokenomics, and Base's powerful distribution channels, Hydrex removes the barriers to yield. It's designed as a coordination system where weekly community governance directs HYDX emissions & protocol revenue. Value flows to where liquidity and volume are most productive, based on protocol alignment.

Hydrex

Hydrex ($HYDX) is trending amid community excitement, with many noting its green performance in a sea of red for the broader crypto market. The community is buzzing about a potential partnership with Coinbase's Spindl and highlighting Hydrex as a competitor to $AERO. Some users suggest it has substantial upside potential due to its relatively low market cap.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending as investors discuss its undervaluation compared to competitors and potential benefits from tariffs driving wealth to Singapore, where it has a strong presence. The community is debating whether it is a buying opportunity, with some citing strong fundamentals and growth potential, while others express concern over its performance and connection to Chinese markets. Recent options activity and technical analysis are also fueling the conversation.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

GBTC is trending as Bitcoin approaches previous highs, generating community discussion around potential price targets and the impact of potential new all-time highs. Some anticipate a continued climb, while others suggest caution, watching for potential pullbacks or corrections. The broader conversation includes analysis of technical indicators and the influence of institutional investment.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Investors Pivot to Global Equity ETFs for Wider Market Exposure?

Investors can eye global equity funds as AI bubble fears, U.S. market risks and Fed easing fuel demand for international diversification.

Danish drugmaker Novo Nordisk (NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site, which produces its blockbuster Semaglutide drugs.According to a Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/world-at-work/novo-nordisk-cuts-hit-production-line-jobs-key-us-plant-posts-show-2025-10-07/">report</a>, citing a review of LinkedIn posts, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton, North Carolina, plant and other facilities in the state. It also includes a strategic communications manager and an HR assistant, the report added.The Clayton facility makes Semaglutide, the active ingredient in the company’s blockbuster Wegovy and Ozempic. It also does steps including filling, finishing, and packaging the injections. It will also play a part in the production of the pill version of Wegovy once available, Reuters noted.Notably, Novo announced layoffs in September and forecast billions in annual savings. The company had said that it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark, it said.The restructuring is expected to save eight billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas. Reuters noted that the exact reason and number for layoffs in Clayton are unclear.Shares of NVO stock fell 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘neutral’ territory over the past 24 hours, and message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_7_12_09_AM_png_2205cacccb.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1364" height="120"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>NVO stock fell 31% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grrr-shares-rally-over-4-percent-pre-market-retail-says-stock-should-be-trading-over-40/ch6PBTQR3Wu">GRRR Shares Rally Over 4% Pre-Market, Retail Says Stock Should Be Trading Over $40: ‘Unbelievable! Way, Way Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 

Equity

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 


Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

Diversify With ETFs and Stay Ahead in Volatile Markets

Amid AI bubble worries and tech sell-offs, investors turn to value, consumer staples, gold and international ETFs for diversification.

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered forecast, Bloomberg reported on Friday, citing a company spokesperson.The reduction will apply to employees who are eligible for short-term incentives in Denmark, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-22/novo-to-cut-employee-bonuses-in-denmark-due-to-slower-growth?srnd=homepage-americas">added</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 3% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:574/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_8_54_27_AM_png_454a11d7f9.webp" alt="NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="574" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they expect the stock to hit $80 by the end of the year.<stembedurl>https://stocktwits.com/WallstreetPatron43/message/626170781</stembedurl>Another user said that they expect a lot of shorting on Friday.<stembedurl>https://stocktwits.com/oldmanrizzer/message/626170959</stembedurl>Earlier this week, it was <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">reported</a> that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.NVO stock is down by 36% this year and by 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-sees-near-50-percent-upside-on-ehang/chsZcIERd0M">JPMorgan Sees Near 50% Upside On This Chinese eVTOL Maker: Retail Believes There’s A Lot To Look Forward To</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End

According to Bloomberg, the reduction in bonuses will apply to employees who are eligible for short-term incentives in Denmark.

Retail sentiment around Anheuser-Busch InBev (ABI),&nbsp;the maker of Budweiser and Corona beers, ticked higher, even as a weak quarterly report sent its shares sliding on Thursday.<a href="https://stocktwits.com/symbol/BUD">BUD's U.S.-listed shares</a> dropped over 13%&nbsp;in the previous session, marking their worst day in over five years.On Stocktwits, retail sentiment&nbsp;shifted to 'extremely bullish' by early Friday, up from 'bullish' the day before, as traders&nbsp;viewed the slide as an overreaction and saw it as a buying opportunity. Message volume for BUD rose 1,200% in the past 24-hour period, among the highest for a consumer stock.<figure class="image"><img style="aspect-ratio:1256/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_12_48_05_PM_png_fd95800c98.webp" alt="Screenshot 2025-08-01 at 12.48.05 PM.png" width="1256" height="156"><figcaption>BUD sentiment and message volume as of August 1 | Source: Stocktwits</figcaption></figure>"Not a fan of the company, but this drop is a bit unjustified," said one user<stembedurl>https://stocktwits.com/Reddiot/message/623258303</stembedurl>Another said: "$BUD Buying dat dip, 10% discount? Thank you!" A third user shared a technical chart showing the stock hitting a key long-term support level.<stembedurl>https://stocktwits.com/stocksailor23/message/623228047</stembedurl><stembedurl>https://stocktwits.com/theoptionsplug/message/623173574</stembedurl>AB InBev said revenue grew 3% organically in the second quarter, below market expectations of 3.2% growth. Organic sales volumes, however, were down 1.9%,&nbsp;primarily due to weak sales in Brazil and China, marking the&nbsp;ninth consecutive quarter of declining beer sales.&nbsp;That was significantly below the 0.3% decline analysts had expected.Organic operating profit increased by 6.5%, ahead of analysts' forecasts of 5.7%.The world's largest brewer also reported weaker-than-expected volumes in Europe and the Middle East,&nbsp;which led to disappointment in all regions except North America.A rebound in the home market comes even as beer demand softens in the region. Bank of America has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bof-a-downgrades-miller-lite-brewer-molson-coors-amid-softness-in-us-beer-sales/chmZESFRReS">predicted</a> that U.S. beer volumes will shrink by 4% next year, steeper than its earlier prediction of 1% decline.In early July, AB InBev&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/budweiser-maker-ab-inbev-plans-300m-investment-to-expand-us-production/chi8fifRbZd">announced</a> plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Starbucks-china-operations-jd-tencent-kkr-among-potential-investors/chr3YU9RdGt">Starbucks China Operations: JD, Tencent, KKR Among Potential Investors To Submit Bids - Report</a>

In this photo illustration, Budweiser beer bottles are seen displayed. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'

U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

Danish drugmaker Novo Nordisk (NVO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348">announced</a> on Thursday that it plans to initiate a late-stage development program with its experimental drug Amycretin for adults with obesity or those who are overweight, starting in the first quarter of 2026.Shares of NVO traded 3% higher on Thursday.The decision to advance the study of Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.Amycretin is a single molecule that operates as both GLP-1 receptor agonist and amylin receptor agonist.While GLP-1 receptor agonists work by mimicking the natural hormone GLP-1, Amylin receptor agonists mimic the effects of the natural hormone amylin, reducing appetite. The drug is developed for subcutaneous and oral administration.The company’s popular weight-loss drug Wegovy’s active component is Semaglutide, another GLP-1 receptor agonist.In the first quarter, Wegovy experienced an 85% increase in sales to DKK 17.36 billion ($2.69 billion), while the company’s overall sales within its obesity care segment grew 67% to DKK 18.42 billion.However, last month, the company said that Lars Fruergaard Jørgensen will <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">step down</a> as CEO as per a mutual agreement with the Novo Nordisk board.The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen by about 8% this year and by about 44% over the past 12 months.On Stocktwits, retail sentiment around Novo Nordisk stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_2_12_25_PM_png_81063cab85.webp" alt="Screenshot 2025-06-12 at 2.12.25 PM.png" width="628" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/google-cloud-teams-up-with-databricks-to-scale-gemini-enterprise-adoption/chlgdNHRRGd">Google Cloud Teams Up With Databricks To Scale Gemini Enterprise Adoption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 DKK= 0.16 USD)

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Denmark-headquartered Novo Nordisk (NVO) has <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases-302478417.html">entered</a> into a collaboration and exclusive worldwide license agreement with California-based Deep Apple Therapeutics, Inc. to develop drugs for cardiometabolic diseases, including obesity.Under the terms of the deal, valued at up to $812 million, Deep Apple will discover oral therapies using its AI-based drug discovery platform, and Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.Both companies will collaborate on the research plan, Deep Apple said.Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.Last month, Novo also announced a similar exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases. The company said the deal could be worth up to $2.2 billion.Separately, chipmaker Nvidia (NVDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://nvidianews.nvidia.com/news/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery">announced</a> a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development.“By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk.On Stocktwits, retail sentiment around Novo Nordisk jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_10_20_55_AM_png_f4ab145e9d.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 9% this year and about 44% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-slams-fed-for-not-cutting-rates-post-inflation-report/chlaMlyRbCt">JD Vance Slams Fed For Not Cutting Rates Post Inflation Report, Says Refusal By The Central Bank Is ‘Monetary Malpractice’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels

Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.

Toyota Industries is expected to announce that it will accept a takeover bid from Toyota Motor Corp. (TM) and other group companies as early as Tuesday, Nikkei Asia <a target="_blank" rel="noopener noreferrer nofollow" href="https://asia.nikkei.com/Business/Business-deals/Toyota-Industries-to-announce-acceptance-of-42bn-takeover-bid">reported</a> on Monday.The consortium is expected to take Toyota Industries private after the firm accepts the tender offer, the report added. The takeover bid is estimated to be 6 trillion yen, or approximately $42 billion.Toyota Industries develops and manufactures automobiles and automobile-related products, such as vehicles, engines, car air-conditioning compressors, car electronics components and devices, and stamping dies. It also develops and produces the RAV4 for Toyota Motor.The companies maintained a close relationship after Toyota Motor was spun off from Toyota Industries in 1937.In FY2024, net sales to Toyota Motor accounted for 12.8% of Toyota Industries’ consolidated net sales. As of March 31, 2024, TMC also held 24.7% of Toyota Industries’ voting rights.The carmaker had said in April that it is exploring investing in the potential buyout of its supplier.Toyota is the largest automaker in the world in terms of global sales. In 2024 alone, the company sold 10.8 million vehicles.Last month, the company also said that its worldwide sales and production rose for the fourth consecutive month in April.The company’s global sales jumped 10% to 876,864 units in April on the back of a near 12% jump in sales within Japan and a near 10% increase in sales outside the home country.On Stocktwits, retail investor sentiment about Toyota remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:636/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_1_30_22_PM_png_979a999514.webp" alt="TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits" width="636" height="67"><figcaption>TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> NYSE-listed shares of <a href="https://stocktwits.com/symbol/TM/sentiment">Toyota</a> traded over 1% lower on Monday. The stock is down by about 3% this year and by over 11% over the past 12 months.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/muln-automotive-raises-stake-in-bollinger-motors/chkYEF6RbHg">Mullen Automotive Raises Stake In Bollinger Motors To 95%, Trading Activity Halts As Stock Undergoes Reverse Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided

The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion.

American Century ETF Trust - Avantis International Equity ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

AVDE
American Century ETF Trust - Avantis International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AVDE News

AVDEAmerican Century ETF Trust - Avantis International Equity ETF